We analyzed the results obtained by flow cytometry DNA analysis in prostatic cancer. We considered the diagnostic role of this investigation and the prognostic value observed from correlating the DNA analysis with usual diagnostic and prognostic factors such as staging, grading, PSA, size, etc. Results in literature suggest that further studies are necessary to explain both the biological and cytometrical heterogeneous aspects of this neoplasm.
MobilioG., SchiavoneD., PianonR., CurtiP., BeltramiP., D'AmicoA., ComunaleL.: Il contributo dell'analisi del DNA mediante citometria a flusso nel giudizio prognostico e nella strategia terapeutica dei tumori urologici. In: CorradoF., MaltoniC., CorradoG., FerriC., PalazziniA., PintoC.: I tumori urologici: recenti progressi e nuovi obiettivi della ricerca. Volume I, Monduzzi Editore, Bologna1992, pp. 21–32.
2.
DeitchA.D., StrandM.A., de Vere WhiteR.W.: Deoxyribonucleic acid flow cytometry of benign prostatic disease. J. Urol., 142: 759–762, 1989.
3.
KleinF.A., RatliffJ.E., WhiteF.K.H.: DNA distribution patterns of prostatic tissue obtained at the time of transurethral resection. Urology, 31: 260–265, 1988.
4.
SchiavoneD., CurtiP., TontodonatiM., LazzarettoM., NovellaG., AzzolinaL.S., LestaniM., MobilioG.: L'analisi del DNA mediante FCM nell'iperplasia e nel cancro della prostata. Urologia, 60(2): 170–174, 1993.
5.
BernerA., DanielsenH.E., PetersenE.O., FossaS.D., ReithA., NeslandJ.M.: DNA distribution in the prostate. Anal. Quant. Cytol. Histol., 15(4): 247–252, 1993.
6.
DeitchA.D., de Vere WhiteR.: Flow cytometry as a predictive modality in prostate cancer. Human Pathol., 23(4): 352–359, 1992.
7.
KonchubaA.M., SchellhammerP.F., KolmP., WrightG.L.Jr.: Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology. J. Urol., 150(1): 115–119, 1993.
8.
Mc IntireT., MurphyW.M., CoonJ.S., ChandlerR.W., SchwartzD., ConwayS., WeinsteinR.S.: The prognostic value of DNA ploidy combined with histologic sustaging for incidental carcinoma of the prostate gland. Am. J. Clin. Pathol., 89(3): 370–373, 1988.
9.
PetersJ.M., MilesB.J., KubusJ.J., CrissmanJ.D.: Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. Anal. Quant. Cytol. Histol., 12: 359–365, 1990.
10.
WinklerH.Z., RainwaterL.M., MyersR.P., FarrowG.M., TherneauT.M., ZinkeH., LieberM.M.: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin. Proc, 63: 103–112, 1988.
11.
ZinckeH., BergstralhE.J., Larson-KellerJ.J., FarrowG.M., MyersR.P., LieberM.M., BarrettD.M., RifeC.C., GonchoroffN.J.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer, 70: 311–323, 1992.
12.
JonesE.C., McNealJ., BruchovskyN., de JongG.: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer, 66: 752–757, 1990.
13.
Mc NealJ.E., BostwickD.G., KindrachukR.A., RedwineE.A., FreihaF.S., StameyT.A.: Patterns of progression in prostate cancer. Lancet, 11(1): 60–63, 1986.
14.
TerresM.K., McNealJ.E., StameyT.A.: Estimate of prostate cancer volume by transitional ultrasound imaging. J. Urol., 147: 855–857, 1992.
15.
BadalamentR.A., O'TooleR.V., YoungD.C., DragoJ.R.: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer, 67: 3014–3023, 1991.
